As shown by Figure 8, the meta-analysis further revealed that there was, also, no significant difference in OS between immune checkpoint inhibitors and chemotherapy for NSCLC patients with KRAS wild-type (HR, 0.9; 95% CI, 0.71–1.16). This evidence concerns the gene KRAS and non-small cell lung carcinoma.